Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D

NCT02017171 is registered in ClinicalTrials.gov with Alessandro Doria as lead sponsor.

NCT NCT02017171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02017171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Lead sponsor
Alessandro Doria
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2014
Completion date
August 31, 2019
Enrollment
530 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, diabetic nephropathies